Project description
Fast and accurate diagnosis of inflammatory bowel disease will foster early relief
Inflammatory bowel disease (IBD) includes Crohn's disease and ulcerative colitis. These chronic, relapsing conditions result in debilitating physical and psychosocial symptoms that can also lead to life-threatening complications. IBD affects approximately 5 million people worldwide, is difficult to diagnose, leading to delay in treatment, and there is no cure. The EU-funded IBDetect project is carrying out Phase I feasibility studies on its world-first point-of-care diagnostic system by the same name. IBDetect can diagnose both Crohn's disease and ulcerative colitis with very high accuracy in their very early, presymptomatic stages with a rapid, minimally invasive and low-cost test based on the specific immune response reflecting alterations in the gut microbiome. Commercialisation is expected to significantly enhance early diagnosis of IBD, resulting in faster initiation of therapies and improved outcomes for patients.
Objective
Inflammatory bowel disease (IBD) is an umbrella term referring to two hard to diagnose chronic intestinal diseases: ulcerative colitis (UC) and Crohn's disease (CD). IBD is a relapsing condition and diagnosis can be missed if tests are carried out during remission. Thus, the diagnosis of IBD relies on a combination of different tests over a long period. However, for half the patients this results in late diagnosis, a major drawback since often the optimal treatment and management is already affected. Furthermore, IBD diagnosis using current tools (1) can be uncomfortable for patients, (2) carry significant risks including gastrointestinal perforation, and (3) in terms of monetary cost are expensive. Thus, in recent years researchers have been investigating the role of the gut microbiome in IBD, hoping to identify trademark features that could speed up diagnosis and combat the increasing prevalence of IBD in western socities. However, until now the use of this approach has been limited in the field of routine clinical diagnostics due to several limitations. After years of R&D, IPDx has overcome these concerns and introduces IBDetect: the world´s first single test for the differential detection of IBD. It can be used discriminate between the two different types of IBD from a very early, pre-symptomatic stage. All of this can be done in a minimally invasive, cost- and time-effective way with remarkable accuracy. IBDetect can be used to decrease the mean time to diagnosis in UC and CD as well as benefit the optimal treatment and management of these diseases. Our primary target group include gastroenterologists in European hospitals and medical centres in the US. We address the global in vitro diagnostics market in which the IBD-related gastrointestinal diagnostics segment is estimated to reach over €7 billion by 2026. During the Phase 1 study IPDx will conduct a comprehensive feasibility study that includes both technical and commercialisation aspects of the innovation.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine gastroenterology inflammatory bowel disease
- natural sciences biological sciences microbiology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
12618 Tallinn
Estonia
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.